drugset / Trial / NCT06209398

Immunogenicity of the Inactivated EV71 Vaccine Combined With Hepatitis B and Group A Meningococcal Vaccine

NCT06209398

RandomizedParallel-groupOpen-labelPrevention

Summary

The main purpose of this study is to evaluate the immunogenicity and safety of inactivated enterovirus type 71 vaccine combined with recombinant hepatitis B vaccine or Group a meningococcal polysaccharide vaccine.

Timeline

Start
2018-05-24
Primary completion
2024-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Group A meningococcal polysaccharide vaccine Vaccine 0.5 ml Subcutaneous
Subject Menjugate Vaccine 0.5 ml Intramuscular
Subject recombinant hepatitis B vaccine Vaccine 0.5 ml Intramuscular